Augustin, M; Mrowietz, U; Dauden, E; Weger, W; Maul, JT; Zurich, G; Laws, P; Naldi, L; Mburu, S; de Jong, E; Kasujee, I; Sommer, R.
Tildrakizumab improves high burdensome symptoms and overall well-being in patients with moderate-to-severe plaque psoriasis
J AM ACAD DERMATOL. 2025; 93(3): AB328-AB328.
Web of Science